Study guide
2.2 Molecular Mechanisms of Antimicrobial Resistance
Board Certified Infectious Diseases Pharmacist BCIDP
Track your progress as you read
Finished sections get a check mark.
1 Causes of Infectious Diseases
1.1 Bacterial Pathogens: Gram-Positive, Gram-Negative, and Atypical Organisms 1.2 Viral Pathogens: Respiratory, Herpesviruses, Hepatitis, and Emerging Viruses 1.3 Fungal Pathogens: Yeasts, Molds, and Dimorphic Fungi 1.4 Parasitic and Vector-Borne Pathogens: Protozoa and Helminths
2 Microbiology Diagnostics, Resistance & Host Response
2.1 Diagnostic Microbiology: Phenotypic, Molecular, and Rapid Diagnostic Methods 2.2 Molecular Mechanisms of Antimicrobial Resistance 2.3 Microbial Virulence Factors, Toxins, and Biofilm Dynamics 2.4 Host Immune Response to Infection and Immunopathology
3 Clinical Assessment & Diagnostic Evaluation
3.1 Clinical Assessment, Infection Screening, and Severity Stratification 3.2 Diagnostic Biomarkers and Clinical Laboratory Interpretation 3.3 Social Determinants of Health and Disparities in Infectious Diseases
4 Pharmacokinetics, Pharmacodynamics & Special Populations
4.1 Pharmacokinetic and Pharmacodynamic Optimization of Antimicrobials 4.2 Host and Environmental Risk Factors for Infection 4.3 Antimicrobial Dosing and Considerations in Special Populations
5 Respiratory and Skin/Soft Tissue Infections
5.1 Pharmacotherapy of Upper and Lower Respiratory Tract Infections 5.2 Pharmacotherapy of Skin and Soft Tissue Infections
6 Cardiovascular, Bone, and Joint Infections
6.1 Pharmacotherapy of Infective Endocarditis and CIED Infections 6.2 Pharmacotherapy of Osteomyelitis, Septic Arthritis, and PJI
7 Central Nervous System and Abdominal Infections
7.1 Pharmacotherapy of Central Nervous System Infections 7.2 Pharmacotherapy of Intra-abdominal, Hepatic, and GI Infections
8 Urologic, Gynecologic, and Sexually Transmitted Infections
8.1 Pharmacotherapy of Urinary Tract and Gynecologic Infections 8.2 Pharmacotherapy of Sexually Transmitted Infections
9 HIV Infection and Opportunistic Infections
9.1 Antiretroviral Therapy and Management of HIV-1 Infection 9.2 Prophylaxis and Management of HIV-Associated Opportunistic Infections
10 Infections in Immunocompromised Hosts and Complex Syndromes
10.1 Infections in Solid Organ Transplant and Hematologic Malignancy 10.2 Sepsis, Septic Shock, and Systemic Complications
11 Medication Administration and Adjunctive Therapies
11.1 Antimicrobial Administration, Vascular Access, and Stability 11.2 Adjunctive Pharmacotherapies and Supportive Care in Serious Infections 11.3 Assessment of Therapeutic Outcomes and Infection Failure
12 Therapeutic Drug Monitoring, Toxicity, and De-escalation
12.1 Therapeutic Drug Monitoring and Precision Pharmacokinetics 12.2 Antimicrobial Adverse Drug Events and High-Risk Drug Interactions 12.3 Antimicrobial De-escalation and IV-to-Oral Transition Strategies
13 Care Transitions, Patient Counseling & Travel Medicine
13.1 Outpatient Parenteral and Complex Oral Antimicrobial Therapy (OPAT/COPAT) 13.2 Patient and Caregiver Counseling, Education, and Adherence 13.3 Travel Medicine, Immunizations, and Prophylactic Regimens
14 Antimicrobial Stewardship Operations, Metrics & Resistance
14.1 Antimicrobial Stewardship Core Elements and Regulatory Mandates 14.2 Stewardship Metrics: Days of Therapy (DOT), DDD, and SAAR 14.3 Surveillance and Tracking of Antimicrobial Resistance Patterns 14.4 Cumulative Antibiogram Construction and CLSI M39 Analysis
15 Formulary Management, Infection Prevention & Population Health
15.1 Antimicrobial Formulary Management and Restriction Strategies 15.2 Public Health, Disease Reporting, and Adult Immunization Strategies 15.3 Healthcare Infection Prevention and Environmental Transmission
16 Literature Evaluation, Informatics & Quality Improvement
16.1 Infectious Diseases Information Resources, Databases, and Clinical Guidelines 16.2 Critical Literature Evaluation and Biostatistical Interpretation 16.3 Quality Improvement Methodologies and Medication Safety in ID 16.4 Clinical Informatics, Decision Support Systems, and Automated Alerts
2.2 Molecular Mechanisms of Antimicrobial Resistance
Key Takeaways Explain This Topic AI
Ambler Class A (KPC) and Class D (OXA-48-like) carbapenemases utilize an active-site serine mechanism, whereas Class B metallo-beta-lactamases (NDM, VIM, IMP) are zinc-dependent and resist all non-metallo beta-lactamase inhibitors.
Chromosomal AmpC cephalosporinases in Enterobacter cloacae, Klebsiella aerogenes, and Citrobacter freundii are inducible upon exposure to weak inducers; clinical failure occurs if third-generation cephalosporins are used due to stable derepression.
Staphylococcal methicillin resistance is conferred by mecA/mecC encoding PBP2a, which has low binding affinity for all conventional beta-lactams with the exception of ceftaroline.
Vancomycin resistance in enterococci results from vanA/vanB operon-mediated alteration of peptidoglycan cell-wall precursors from D-Ala-D-Ala to D-Ala-D-Lac, decreasing glycopeptide binding affinity 1,000-fold.
Inducible MLSB resistance via erm gene 23S rRNA methylation requires laboratory detection via the double-disk diffusion D-test; failure to recognize blunted clindamycin inhibition zones risks clinical treatment failure.
Last updated: October 2026
Molecular Mechanisms of Antimicrobial Resistance
Bacterial resistance to antimicrobial agents represents an evolving clinical challenge driven by complex genetic and biochemical mechanisms. Bacteria deploy four fundamental strategies: enzymatic drug inactivation, modification of drug binding targets, decreased membrane permeability, and active extrusion via multidrug efflux pumps. Mastery of these molecular pathways is essential for selecting effective antimicrobial regimens and anticipating clinical failure.
Enzymatic Inactivation: Beta-Lactamases
Beta-lactamases hydrolyze the amide bond within the four-membered beta-lactam ring, rendering the antibiotic microbiologically inactive. The Ambler molecular classification categorizes beta-lactamases into four distinct classes (A, B, C, D) based on primary amino acid sequence homology and catalytic mechanism. ┌──────────────────────────────────────────────┐
- │ Ambler Classification Scheme │
- └──────────────────────┬───────────────────────┘
- │
- ┌───────────────────────────────┴───────────────────────────────┐
- ▼ ▼
- ┌───────────────────────────────┐ ┌───────────────────────────────┐
- │ Serine Beta-Lactamases │ │ Metallo-Beta-Lactamases (MBL) │
- │ (Active-site Serine Hydrolase)│ │ (Zinc Divalent Cations) │
- └───────────┬───────────────────┘ └───────────────┬───────────────┘
- │ │
- ┌────────┼────────┐ ▼
- ▼ ▼ ▼ Class B
- Class A Class C Class D (NDM, VIM, IMP, SPM)
- (TEM, (AmpC) (OXA-48, - Hydrolyze carbapenems
- SHV, OXA-23) - Inactivated by EDTA
- CTX-M, - Resist CAZ-AVI, MER-VAB
- KPC) - Sparingly active: Cefiderocol,
- Aztreonam + Avibactam
- Ambler Class Overview
Ambler Class Catalytic Mechanism Representative Enzymes Hydrolysis Profile Susceptibility / Inhibitor Profile
Class A Serine active site TEM-1, SHV-1 (narrow); CTX-M-14/15, SHV-5 (ESBL); KPC-2/3 (Carbapenemase) Narrow-spectrum: penicillins. ESBL: Penicillins, cephalosporins (including cefepime), aztreonam. KPC: All beta-lactams including carbapenems. ESBLs inhibited by clavulanate, tazobactam, avibactam, vaborbactam, relebactam. KPC inhibited by avibactam, vaborbactam, relebactam. MERINO trial established carbapenems as drug of choice for severe ESBL infections.
Class B Metallo-enzymes requiring active-site Z n 2 + Zn^{2+} Z n 2 + NDM-1, VIM-1, IMP-1 Hydrolyzes penicillins, cephalosporins, and carbapenems. Spares aztreonam (monobactam). Not inhibited by any approved serine beta-lactamase inhibitor (clavulanate, tazobactam, avibactam, vaborbactam, relebactam). Inhibited in vitro by metal chelators (EDTA). Clinically managed with aztreonam-avibactam (Emblaveo, FDA-approved February 2025 for complicated intra-abdominal infection with metronidazole), the older improvised ceftazidime-avibactam + aztreonam (CZA+ATM) combination, or cefiderocol .
Class C Serine active site Chromosomal AmpC ( E. cloacae , K. aerogenes , C. freundii ); plasmid AmpC (CMY, FOX, DHA) Penicillins, first-, second-, and third-generation cephalosporins (ceftriaxone, ceftazidime), cephamycins (cefoxitin), monobactams. Poorly inhibited by clavulanate/tazobactam. Inhibited by avibactam, relebactam, vaborbactam. Cefepime retains low-to-moderate stability against AmpC if MIC ≤ 2 mg/L \le 2\text{ mg/L} ≤ 2 mg/L . Carbapenems are definitive therapy for severe high-inoculum infections.
Class D Serine active site OXA-48-like ( K. pneumoniae ); OXA-23, OXA-24/40, OXA-58 ( A. baumannii ) Variable: OXA-48 hydrolyzes penicillins and carbapenems; weakly hydrolyzes third-generation cephalosporins unless an ESBL is co-produced. Resistant to clavulanate and EDTA. OXA-48 is inhibited by avibactam (CZA active), but not by vaborbactam or relebactam. Acinetobacter OXA enzymes confer extreme carbapenem resistance and are poorly inhibited by avibactam.
Inducible Chromosomal AmpC Cephalosporinases
Certain Gram-negative species harbor an inducible chromosomal ampC gene regulated by ampR (transcriptional regulator), ampG (permease), and ampD (cytosolic amidase). Historically grouped under mnemonics such as SPACE ( Serratia , Pseudomonas , Acinetobacter , Citrobacter , Enterobacter ) or HECK ( Hafnia , Enterobacter , Citrobacter , Klebsiella aerogenes ), contemporary clinical data demonstrate that the risk of clinically significant, stable derepression is highest in three core organisms:
- Enterobacter cloacae complex
- Klebsiella aerogenes (formerly Enterobacter aerogenes )
- Citrobacter freundii
Important
When Enterobacter cloacae , Klebsiella aerogenes , or Citrobacter freundii are isolated, initial in vitro AST may demonstrate false susceptibility to ceftriaxone or ceftazidime. Exposure to these weak inducers leads to selection of mutant subpopulations possessing mutations in ampD , causing permanent hyperproduction (stable derepression) and rapid clinical treatment failure. Ceftriaxone should be avoided regardless of reported in vitro susceptibility. Cefepime is acceptable only if the MIC is ≤ 2 mg/L \le 2\text{ mg/L} ≤ 2 mg/L ; carbapenems remain the gold standard for high-inoculum deep-seated infections.
- Other Enzymatic Inactivation Mechanisms
- Aminoglycoside-Modifying Enzymes (AMEs)
Aminoglycosides exert bactericidal activity by binding the 30S ribosomal subunit. Resistance occurs through plasmid-borne enzymes that chemically modify hydroxyl or amino functional groups on the aminoglycoside core, stericly blocking ribosomal binding:
Acetyltransferases (AAC): Catalyze acetyl-CoA-dependent acetylation of amino groups (e.g., AAC(6')-Ib confers resistance to tobramycin, amikacin, and kanamycin).
Phosphotransferases (APH): Catalyze ATP-dependent phosphorylation of hydroxyl groups (e.g., APH(3')-Ia confers resistance to neomycin and kanamycin).
Nucleotidyltransferases (ANT): Catalyze ATP-dependent adenylylation of hydroxyl groups (e.g., ANT(2")-Ia confers resistance to gentamicin and tobramycin).
Plazomicin is a synthetic next-generation aminoglycoside engineered with a hydroxy-aminobutyric acid (HABA) substituent and an unsaturated hydroxyethyl side chain that blocks steric binding of nearly all clinically prevalent AMEs, maintaining potent activity against CRE and ESBL-producing isolates. However, plazomicin is inactivated by 16S ribosomal RNA methyltransferases (such as ArmA and RmtB), which confer pan-aminoglycoside resistance.
Macrolide Inactivation
Bacteria produce macrolide esterases ( ereA , ereB ) that hydrolyze the 14- or 15-membered lactone ring of erythromycin and azithromycin, or macrolide phosphotransferases ( mphA ) that phosphorylate the 2'-hydroxyl group of the desosamine sugar.
Target Site Alterations
Target site modification prevents antimicrobial binding through point mutations in target genes, post-transcriptional ribosomal methylation, or acquisition of alternative biosynthetic enzymes. Target Site Alteration Mechanisms:
- ├── PBP Alteration (mecA/mecC -> PBP2a) ─────────► Staphylococcal Methicillin Resistance (MRSA)
- ├── Peptidoglycan Precursor (D-Ala-D-Ala -> D-Ala-D-Lac) ► Enterococcal Vancomycin Resistance (vanA/vanB)
- ├── 23S rRNA Methylation (ermA/B/C) ─────────────► Inducible MLSB Phenotype (Clindamycin Resistance)
- ├── Topoisomerase Mutations (gyrA / parC) ──────► Fluoroquinolone Resistance (Ciprofloxacin/Levofloxacin)
- └── RNA Polymerase Beta Subunit (rpoB) ──────────► Rifampin Resistance
- Staphylococcal Methicillin Resistance: mecA and mecC
Methicillin resistance in Staphylococcus aureus (MRSA) and coagulase-negative staphylococci is mediated by the mobile genetic element Staphylococcal Cassette Chromosome mec (SCC mec ). This element carries mecA (or its divergent homolog mecC ), which encodes penicillin-binding protein 2a (PBP2a). While native PBPs (PBP1, PBP2, PBP3) are acylated and inactivated by beta-lactams, PBP2a possesses an altered active-site geometry with an exceptionally low binding affinity for penicillins, cephalosporins, and carbapenems. PBP2a continues transpeptidating cell wall peptidoglycan despite therapeutic beta-lactam concentrations.
Exceptions: Ceftaroline and ceftobiprole are advanced-generation cephalosporins designed to bind an allosteric pocket on PBP2a, triggering a conformational change that permits high-affinity active-site acylation and staphylocidal activity.
Enterococcal Vancomycin Resistance: van Gene Operons
Vancomycin binds with high affinity to the C-terminal D-alanyl-D-alanine (D-Ala-D-Ala) terminus of peptidoglycan lipid II pentapeptide precursors via five hydrogen bonds, blocking transglycosylation and transpeptidation.
vanA Operon: Acquired plasmid-mediated transposable element (Tn 1546 ) triggered by vancomycin or teicoplanin. Encodes VanA (ligase synthesizing D-alanyl-D-lactate [D-Ala-D-Lac]), VanX (D,D-dipeptidase cleaving native D-Ala-D-Ala), and VanY (carboxypeptidase). The substitution of an ester linkage (lactate) for an amide linkage eliminates one critical hydrogen bond, reducing vancomycin binding affinity by ~1,000-fold. Results in high-level resistance to both vancomycin (MIC ≥ 64 mg/L \ge 64\text{ mg/L} ≥ 64 mg/L ) and teicoplanin.
vanB Operon: Synthesizes D-Ala-D-Lac, but transcription is induced exclusively by vancomycin, not teicoplanin. Isolates appear resistant to vancomycin but susceptible in vitro to teicoplanin (though teicoplanin resistance emerges readily during therapy).
vanC Phenotype: Native, chromosomal, non-transferable low-level resistance found constitutively in Enterococcus gallinarum and Enterococcus casseliflavus . Involves alteration to D-alanyl-D-serine (D-Ala-D-Ser), producing moderate vancomycin MICs (typically 4–32 mg/L) without teicoplanin cross-resistance.
Inducible M L S B MLS_B M L S B Resistance and the D-Test
Macrolides (erythromycin, azithromycin), lincosamides (clindamycin), and streptogramin B compounds share overlapping binding sites on the 23S rRNA component of the bacterial 50S ribosomal subunit ( M L S B MLS_B M L S B group).
Mechanism: The erm (erythromycin ribosome methylase) gene family ( ermA , ermB , ermC ) encodes methyltransferases that add one or two methyl groups to adenine residue A2058 in the 23S rRNA. This sterically impedes binding of all M L S B MLS_B M L S B agents.
Phenotypes:
Constitutive M L S B MLS_B M L S B : Continuous enzyme expression; isolate tests resistant in vitro to both erythromycin and clindamycin.
Inducible M L S B MLS_B M L S B : Enzyme synthesis is repressed until an inducer is present. 14- and 15-membered macrolides (erythromycin) are strong inducers of the erm mRNA attenuator; clindamycin is a weak inducer. Consequently, in vitro disk diffusion or automated AST displays erythromycin resistance but apparent clindamycin susceptibility.
Efflux-mediated resistance ( m s r A msrA m sr A / m e f A mefA m e f A ): Operates an active efflux pump specific for macrolides; clindamycin remains fully active and susceptible without risk of failure.
Warning
If an isolate of Staphylococcus or Streptococcus tests resistant to erythromycin but susceptible to clindamycin, the microbiology laboratory must perform a double-disk diffusion induction test (D-zone test). An erythromycin disk (15 mcg) is placed 15 to 26 mm adjacent to a clindamycin disk (2 mcg). If the erm gene is present, erythromycin diffuses toward clindamycin and induces methylase production, producing a blunted, "D-shaped" clearing zone around clindamycin. A positive D-test requires reporting clindamycin as Resistant , as clindamycin therapy risks clinical failure through rapid selection of constitutive mutants.
Fluoroquinolone and Rifampin Target Mutations
Fluoroquinolones: Inhibit DNA gyrase ( gyrA , gyrB ) and topoisomerase IV ( parC , parE ), halting bacterial DNA replication. High-level resistance develops stepwise through non-synonymous point mutations in the Quinolone Resistance-Determining Regions (QRDR), typically Ser83Leu and Asp87Asn in gyrA combined with Ser80Ile in parC .
Rifampin: Inhibits bacterial DNA-dependent RNA polymerase by binding the β \beta β -subunit ( rpoB ). A single point mutation within the conserved 81-base-pair rifampin resistance-determining region (RRDR) of rpoB (such as His526Tyr or Ser531Leu) confers complete, high-level clinical resistance. Rifampin must never be deployed as monotherapy for active bacterial infections.
- Decreased Permeability and Efflux Systems
- Porin Loss in Pseudomonas aeruginosa
Gram-negative outer membranes contain non-specific and substrate-specific protein channels called porins. In P. aeruginosa , entry of carbapenems into the periplasmic space depends upon the OprD outer membrane porin. Mutational disruption, transcriptional downregulation, or loss of oprD abolishes carbapenem penetration. Because imipenem depends strictly on OprD while meropenem relies partially on alternative channels, oprD silencing produces profound imipenem resistance while meropenem MICs may exhibit only moderate elevation.
Multidrug Resistance (MDR) Efflux Pumps
Efflux pumps span the inner membrane, periplasm, and outer membrane to actively export antimicrobials:
Pseudomonas aeruginosa (Mex Systems): Resistance-Nodulation-Division (RND) tripartite family systems:
MexAB-OprM: Overexpression confers resistance to beta-lactams (piperacillin, ceftazidime, cefepime, meropenem), fluoroquinolones, and tetracyclines. Note that imipenem is not an efflux substrate for MexAB-OprM.
MexXY-OprM: Overexpression exports aminoglycosides, fluoroquinolones, and cefepime.
Acinetobacter baumannii (AdeABC): RND pump conferring multidrug resistance across aminoglycosides, beta-lactams, fluoroquinolones, and tigecycline.
Colistin and Polymyxin Resistance
Polymyxins (colistin [polymyxin E] and polymyxin B) act by electrostatic binding to negatively charged phosphate groups on Lipid A of Gram-negative lipopolysaccharide (LPS), displacing stabilizing M g 2 + Mg^{2+} M g 2 + and C a 2 + Ca^{2+} C a 2 + ions to disrupt outer membrane integrity.
Target Modification: Resistance occurs via the covalent addition of positively charged moieties—phosphoethanolamine (pEtN) or 4-amino-4-deoxy-L-arabinose (L-Ara4N)—to Lipid A, neutralizing its negative charge and abolishing polymyxin binding affinity.
Chromosomal Mutations: Alterations in two-component sensor kinase/regulator systems ( pmrA/pmrB , phoP/phoQ ) or loss-of-function mutations in mgrB (a negative regulator of PhoP/PhoQ in K. pneumoniae ) cause constitutive hyper-activation of the arnBCADTEF lipid modification operon.
Plasmid-Mediated Resistance ( mcr Genes): mcr-1 through mcr-10 encode phosphoethanolamine transferases on transmissible plasmids, facilitating horizontal interspecies dissemination of polymyxin resistance among Enterobacterales .